18+ · Research Use Only · Not for Human Consumption
Retatrutide · Phase 2 · Completed
Retatrutide phase 2 (Jastreboff)
In Retatrutide phase 2 (Jastreboff), a phase 2 trial of retatrutide in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition (n=338), mean body weight fell 8.7% on 1 mg, 17.1% on 4 mg (pooled), 22.8% on 8 mg (pooled) and 24.2% on 12 mg over 48 weeks, against 2.1% on placebo (Jastreboff AM et al. N Engl J Med 2023;389:514-526).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Results
Side effects reported
Retatrutide phase 2 (Jastreboff): The abstract reports gastrointestinal events as the most common, dose-related and mostly mild to moderate, without rates; rates by arm are in the full text, not read here.
Design
Trial design and sources
- Compound
- Retatrutide
- Phase
- 2
- Population
- Adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition
- Participants randomised
- 338
- Duration
- 48 weeks
- Primary endpoint
- Percent change in body weight from baseline at 24 weeks; 48 weeks secondary
- Estimand
- Not stated in the source read
- Read out
- 26 June 2023
48-week figures (least-squares mean). At the 24-week primary endpoint the arms were -7.2%, -12.9%, -17.3% and -17.5% against -1.6% on placebo. The abstract reports gastrointestinal events as the most common, dose-related and mostly mild to moderate, without rates; rates by arm are in the full text, not read here.
Questions
Retatrutide phase 2 (Jastreboff), answered
What did Retatrutide phase 2 (Jastreboff) find?
In Retatrutide phase 2 (Jastreboff), a phase 2 trial of retatrutide in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition (n=338), mean body weight fell 8.7% on 1 mg, 17.1% on 4 mg (pooled), 22.8% on 8 mg (pooled) and 24.2% on 12 mg over 48 weeks, against 2.1% on placebo (Jastreboff AM et al. N Engl J Med 2023;389:514-526).
What side effects were reported in Retatrutide phase 2 (Jastreboff)?
Retatrutide phase 2 (Jastreboff): The abstract reports gastrointestinal events as the most common, dose-related and mostly mild to moderate, without rates; rates by arm are in the full text, not read here.